Glimith-MF 2mg/500mg Tablet SR
Marketer
Johnlee Pharmaceuticals Pvt Ltd
Salt Composition
Glimepiride (2mg) + Metformin (500mg)
Overview Glimith-MF 2mg/500mg Tablet SR
Diabetic patients treated with the dual-action medication, Glimith-MF 2mg/500mg SR tablets, experience improved blood glucose management. This anti-diabetic formulation, combining two active agents, is indicated for adult type 2 diabetes mellitus. Optimal efficacy is achieved through consistent, daily ingestion with meals, at the same time each day, as prescribed by your physician. Dosage adjustments may occur based on your blood glucose readings and treatment response. Discontinuing Glimith-MF without medical consultation is strongly discouraged; abrupt cessation risks elevated blood sugar, potentially leading to severe complications like nephropathy, retinopathy, neuropathy, and peripheral vascular disease. This medication forms one component of a comprehensive diabetes management plan, necessitating adherence to a balanced diet, regular exercise, and weight management as directed by your healthcare provider. Lifestyle modifications are pivotal in diabetes control. Hypoglycemia (low blood sugar) is a prevalent adverse effect, characterized by symptoms including tremors, sweating, dizziness, and cephalalgia. Prompt glucose replenishment (e.g., sugary snacks, fruit juice) is crucial. Alcohol consumption should be limited to mitigate hypoglycemic risk. Additional potential side effects include gastrointestinal upset (nausea, diarrhea, abdominal pain), altered taste perception, headaches, upper respiratory infections, and weight gain. Contraindications include type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Patients with a history of cardiovascular disease should inform their physician before commencing treatment. Glimith-MF should be used cautiously in pregnancy and lactation, with prior consultation with your doctor mandatory. Regular blood glucose monitoring, along with periodic blood tests evaluating hematological parameters and liver function, are recommended.
Primary Ingredients of Glimith-MF 2mg/500mg Tablet SR
The provided text is "undefined," which offers no content to rephrase. Therefore, no rewritten text can be provided.
Uses of Glimith-MF 2mg/500mg Tablet SR
Managing type 2 diabetes
Major Benefits of Glimith-MF 2mg/500mg Tablet SR:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment duration. Ingest the entire tablet without chewing, crushing, or breaking it. Consume Glimith-MF 2mg/500mg Extended-Release Tablets with food.
Common Side effects of Glimith-MF 2mg/500mg Tablet SR:
- Headache
- Hypoglycemia (low blood glucose level)
- Nausea
- Diarrhea
How to use Glimith-MF 2mg/500mg Tablet SR:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the Glimith-MF 2mg/500mg Tablet SR whole; avoid chewing, crushing, or breaking it. Administer this extended-release tablet with a meal.
How Glimith-MF 2mg/500mg Tablet SR works:
Glimepiride/Metformin 2mg/500mg Extended-Release Tablets (Glimith-MF) combine two distinct antidiabetic agents to manage blood sugar. Glimepiride, a sulfonylurea, stimulates pancreatic insulin secretion, thus reducing blood glucose levels. Metformin, a biguanide, acts by decreasing hepatic glucose production, retarding intestinal glucose absorption, and enhancing insulin sensitivity.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol and Glimith-MF 2mg/500mg SR tablet use poses a safety risk.
PregnancyCONSULT YOUR DOCTOR
The extended-release Glimith-MF 2mg/500mg tablet may pose pregnancy risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingUNSAFE
Extended-release Glimith-MF tablets (2mg/500mg) are contraindicated for breastfeeding mothers. Evidence indicates potential infant toxicity from this medication.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if such symptoms arise.
KidneyCAUTION
Patients with kidney impairment should exercise caution when using Glimith-MF 2mg/500mg SR tablets, as dose modification may be necessary. Consult a physician for guidance. Glimith-MF 2mg/500mg SR tablets are contraindicated in individuals with severe kidney disease. Close monitoring of renal function is recommended during treatment.
LiverCAUTION
For individuals with liver impairment, the use of Glimith-MF 2mg/500mg SR tablets requires careful consideration. Dosage modification of Glimith-MF 2mg/500mg SR tablets may be necessary. Medical advice is recommended. In patients experiencing mild to moderate hepatic dysfunction, Glimith-MF 2mg/500mg SR tablets are typically initiated at a reduced dosage; however, their use is contraindicated in those with severe liver disease.
What if you forget to take Glimith-MF 2mg/500mg Tablet SR :
Should you forget a dose of your Glimith-MF 2mg/500mg SR tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glimith-MF 2mg/500mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently